With new genomic testing to establish probability of metastasis or progression to higher level disease, it may be even easier to examine, in consultation with treating doctors, the feasibility of continuing active surveillance and avoiding, as far as possible, repeat biopsies and depending instead on biomarker and imaging based confirmation of non-progression.